Drugs Containing Excipient (Inactive Ingredient) PROTAMINE SULFATE

« Back to Dashboard

Branded drugs containing PROTAMINE SULFATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	HUMULIN	insulin human	50090-0352	PROTAMINE SULFATE
A-S Medication Solutions	NOVOLIN	human insulin	50090-0403	PROTAMINE SULFATE
A-S Medication Solutions	HUMULIN	insulin human	50090-0444	PROTAMINE SULFATE

Generic drugs containing PROTAMINE SULFATE excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	insulin lispro	0002-7511	PROTAMINE SULFATE
Eli Lilly and Company	insulin lispro	0002-7512	PROTAMINE SULFATE
Eli Lilly and Company	insulin lispro	0002-8233	PROTAMINE SULFATE

Protamine Sulfate Market Dynamics, Financial Trajectory, Patents, and Supply Outlook

Last updated: August 12, 2026

Protamine sulfate is a specialized pharmaceutical protein with two commercial roles: an injectable medicine that reverses unfractionated and low-molecular-weight heparin, and a formulation component used in protamine-based insulin products. Its market is small relative to conventional excipients but strategically important because production depends on constrained biological raw materials, validated purification, sterile manufacturing, and regulatory control.

Public companies generally do not report protamine sulfate revenue as a standalone line item. The product is usually included within hospital injectable portfolios, insulin formulations, or broader specialty pharmaceutical sales. The most defensible financial view is therefore directional rather than a precise market-size estimate.

What is protamine sulfate and how is it used?

Protamine sulfate is a strongly basic protein mixture that binds the acidic heparin molecule and neutralizes its anticoagulant effect. It is administered intravenously after procedures involving unfractionated heparin and, in selected cases, to partially reverse low-molecular-weight heparin.

Protamine is also combined with insulin to delay absorption. Isophane insulin, commonly known as NPH insulin, contains insulin complexed with protamine and zinc. In that application, protamine is a formulation component rather than the principal therapeutic mechanism.

Application	Commercial role	Demand driver
Heparin reversal	Active injectable drug	Cardiac surgery, vascular procedures, heparin overdose
NPH insulin	Formulation component	Diabetes treatment and human insulin manufacturing
Insulin mixtures	Formulation component	Premixed insulin products
Research and laboratory use	Reagent	Nucleic-acid delivery, cell biology, analytical research

The heparin-reversal market has higher regulatory and clinical sensitivity. Insulin use generates more embedded volume but is tied to the production and market share of protamine-containing insulin products.

How large is the protamine sulfate market?

No authoritative public source establishes a universally accepted standalone global market size for protamine sulfate. Published commercial estimates vary because they may include only injectable protamine, raw material for insulin production, laboratory-grade material, or related heparin-reversal products.

A more reliable segmentation is:

1. Injectable protamine sulfate for hospitals and surgery centers.
2. Pharmaceutical-grade protamine used in insulin manufacturing.
3. Research-grade and industrial material.
4. Contract manufacturing and private-label supply.

Hospital injectable protamine is likely the highest-value segment per unit because it requires sterile finished-dose manufacturing, validated potency, container-closure controls, and emergency-stock distribution. Insulin manufacturing represents a more stable industrial demand base but is concentrated among a small number of global insulin producers.

The market is therefore best characterized as low-volume, high-criticality, and supply-constrained rather than as a high-growth mass-volume excipient category.

What is the financial trajectory for protamine sulfate?

The financial trajectory is likely to be modestly positive in value, with growth driven more by pricing, supply security, and formulation demand than by rapid unit expansion.

Financial factor	Directional effect
Cardiovascular and cardiac-surgery activity	Supports demand for injectable protamine
Heparin use in procedures	Supports baseline consumption
Shift to alternative anticoagulants	Limits long-term volume growth
NPH and premixed insulin production	Provides recurring formulation demand
Raw-material scarcity	Raises cost and pricing pressure
Sterile manufacturing requirements	Supports premium pricing
Generic and multi-source competition	Limits excessive price expansion
Hospital shortage concerns	Increase value of dependable supply

Protamine is unlikely to become a high-growth excipient category. Its financial profile is closer to a critical-care specialty ingredient: recurring demand, limited substitution, high quality requirements, and meaningful downside if a producer loses regulatory approval or raw-material access.

Base-case financial outlook

The base case is low-single-digit volume growth or flat volume, combined with intermittent price increases. Revenue can expand faster than volume when manufacturers pass through higher costs for biological raw materials, sterile processing, testing, and compliance.

Upside case

An upside scenario would require one or more of the following:

• Increased cardiac and vascular procedure volumes.
• Greater use of protamine-containing insulin formulations.
• Supply disruptions affecting competitors.
• Hospital purchasing policies that prioritize dual-source or domestic supply.
• New formulation or delivery applications using protamine as a carrier or complexing agent.

Downside case

The main downside risks are:

• Reduced use of unfractionated heparin in favor of newer anticoagulants.
• Further migration from NPH insulin toward analog insulin.
• Safety concerns involving protamine hypersensitivity or pulmonary complications.
• New suppliers entering through lower-cost biological sourcing.
• Procurement substitution toward alternative heparin-reversal practices where clinically appropriate.

Which companies manufacture or supply protamine sulfate?

The commercial supply chain includes finished-dose drug manufacturers, pharmaceutical ingredient suppliers, and insulin producers. Company participation can change through product transfers, facility closures, private-label arrangements, and regional registrations.

The best-known commercial relationships include:

• Pfizer, through legacy hospital injectable products and the protamine sulfate injection product historically marketed under the brand name Protamine Sulfate Injection.
• Sanofi, Novo Nordisk, and Eli Lilly, as major producers of insulin products in which protamine may be used in NPH or premixed formulations.
• Regional generic injectable manufacturers and contract manufacturing organizations.
• Specialized biological ingredient suppliers that sell pharmaceutical-grade protamine or related protamine preparations.

A supplier’s presence in the raw-material market does not establish that it markets an FDA-approved finished injectable. The two businesses require different regulatory evidence, manufacturing controls, and commercial channels.

What is the FDA regulatory status of protamine sulfate?

Protamine sulfate injection is regulated in the United States as a prescription drug and is not merely an excipient when administered for heparin reversal. FDA labeling identifies the product as a heparin antagonist and describes dosing, administration, warnings, and adverse reactions. [1]

Its principal regulatory characteristics are:

Regulatory issue	Assessment
FDA status	Prescription injectable drug
Therapeutic role	Heparin neutralization
Dosage form	Sterile injectable solution
Administration	Intravenous, with controlled rate and monitoring
Principal safety concern	Severe hypersensitivity and hemodynamic reactions
Excipient role	Formulation component in selected insulin products
Regulatory pathway	Drug approval for finished injectable products; drug-substance controls for ingredient supply

The FDA-approved labeling warns that rapid administration can cause severe hypotension, bradycardia, pulmonary hypertension, and anaphylactoid or anaphylactic reactions. These risks make manufacturing consistency and clinical-use controls commercially important. [1]

Protamine used in insulin products is subject to the regulatory requirements applicable to the finished insulin product. Its identity, purity, bioburden, endotoxin profile, and functional performance must be controlled as part of the manufacturer’s overall chemistry, manufacturing, and controls package.

Is protamine sulfate listed in the FDA Orange Book?

The Orange Book is primarily a reference for approved drug products and associated patents or exclusivities. It is not a comprehensive catalog of excipients or active pharmaceutical ingredients.

Protamine sulfate may appear in FDA drug databases through approved finished injectable products, but the commercial status of a specific product, application number, patent listing, and marketing holder must be checked in the current Drugs@FDA and Orange Book records. A standalone protamine sulfate raw-material listing should not be interpreted as an Orange Book-approved product.

For market analysis, the relevant distinction is:

• Finished protamine sulfate injection: potentially subject to application-level approval and Orange Book analysis.
• Protamine raw material used in insulin: controlled within the sponsor’s finished-product regulatory filing.
• Research-grade protamine: generally outside the FDA prescription-drug approval framework.

What patents protect protamine sulfate products?

Protamine sulfate itself is an old biological material, and broad composition-of-matter patent protection is unlikely to provide a meaningful current barrier for the basic substance. Commercial protection is more likely to involve:

• Purification and depyrogenation processes.
• Source-material treatment.
• Protein fractionation and characterization.
• Sterile formulation and container systems.
• Combination products containing protamine and insulin.
• Specific insulin-protamine complexes.
• Manufacturing controls and proprietary analytical methods.

For approved protamine injection, the main competitive barriers are regulatory approval, sterile manufacturing, validated biological sourcing, and hospital purchasing access rather than a broad active patent estate.

Are there Paragraph IV challenges involving protamine sulfate?

Protamine sulfate does not have the same active generic-challenge profile as high-revenue small-molecule products. Publicly visible Paragraph IV activity is more likely to arise around specific finished injectable products than around protamine as a substance.

A Paragraph IV filing would need to target an Orange Book-listed patent for a particular reference product. Historical patents associated with insulin-protamine formulations may also be relevant to specific insulin products, but they do not automatically create protection for injectable protamine sulfate.

No broad, commercially decisive Paragraph IV trend is established for protamine sulfate as a standalone ingredient.

How strong is the patent estate for protamine sulfate?

The patent estate is weak to moderate for the basic molecule and stronger at the process and product level.

Protection layer	Relative strength	Commercial relevance
Basic protamine composition	Low	Material is historically established
Purification process	Moderate	Can limit qualified suppliers
Sterile injectable formulation	Moderate	Relevant to finished-drug competition
Insulin-protamine complex	Product-specific	Relevant to NPH and premixed insulin
Manufacturing know-how	High in practice	Difficult to replicate quickly
Regulatory data package	Moderate to high	Raises entry time and cost
Supply agreements	High commercially	Can restrict access to qualified material

Trade secrets and quality systems may create greater practical protection than issued patents. A new entrant may be able to make a chemically similar protein but still fail to demonstrate consistent potency, low endotoxin levels, acceptable impurity profiles, and reproducible clinical performance.

What manufacturing and supply barriers affect the market?

Protamine sulfate is commonly associated with fish-derived protamines, historically obtained from salmon sperm or related fish sources. Source selection can affect purity, allergen management, supply continuity, cost, and regulatory documentation.

Key manufacturing barriers include:

• Dependence on qualified biological feedstock.
• Variability in source material.
• Protein extraction and fractionation.
• Removal of endotoxin and process impurities.
• Control of molecular-weight distribution and potency.
• Sterile filtration or aseptic processing.
• Stability testing and container compatibility.
• Traceability from source material to finished batch.
• Regional requirements for animal-derived materials.

The supply chain has limited flexibility because switching suppliers may require comparability work, quality audits, regulatory supplements, and validation. Hospitals may also require a reliable emergency supply for use in cardiac and vascular procedures.

Does protamine sulfate face biosimilar competition?

Protamine sulfate does not face biosimilar competition in the conventional sense. Biosimilar regulation applies to biological reference products with an established biologic licensing framework, while protamine sulfate injection is generally treated as a drug product rather than a modern biologic reference medicine.

Competition can arise from:

• Generic or abbreviated injectable products.
• Alternative suppliers of the active ingredient.
• Private-label hospital injectables.
• Formulation changes in insulin.
• Clinical substitution away from protamine where appropriate.

The absence of a biosimilar pathway does not eliminate competitive risk. It shifts competition toward generic drug approval, manufacturing capability, and hospital contracting.

What licensing deals affect protamine sulfate?

Public licensing activity specifically for protamine sulfate is limited. Most commercial arrangements are likely to be supply contracts, contract manufacturing agreements, technology transfers, or integrated insulin manufacturing relationships rather than headline licensing transactions.

Relevant deal structures include:

1. Long-term supply agreements for pharmaceutical-grade protamine.
2. Private-label manufacturing of sterile injectables.
3. Technology transfer for purification and sterile formulation.
4. Insulin manufacturing collaborations involving protamine-containing products.
5. Regional distribution agreements for hospital products.

Because protamine is a critical but relatively low-revenue ingredient, suppliers may protect economics through minimum-volume commitments, qualification requirements, and geographic exclusivity rather than through royalty-bearing patent licenses.

What litigation and settlement risks affect protamine sulfate?

Litigation risk is more likely to involve product liability, manufacturing quality, shortages, procurement disputes, or insulin patents than a direct dispute over protamine composition.

Potential litigation categories include:

• Product-liability claims involving hypersensitivity or hemodynamic events.
• Patent disputes over insulin formulations containing protamine.
• Hatch-Waxman litigation involving a specific injectable reference product.
• Contract disputes over supply interruptions or quality failures.
• Regulatory enforcement involving sterile manufacturing or labeling.
• Antitrust or procurement claims in concentrated hospital markets.

Settlement agreements are therefore more likely to affect particular insulin products or branded injectable products than the protamine sulfate ingredient market as a whole.

How does protamine sulfate compare with other heparin-reversal products?

Protamine has no universally interchangeable replacement for complete reversal of unfractionated heparin. Its strongest competitive pressure comes from changes in anticoagulant selection and procedure protocols rather than from a direct substitute.

Product or approach	Primary use	Relationship to protamine
Protamine sulfate	Reversal of unfractionated heparin	Established standard
Partial reversal protocols	Controlled reduction of anticoagulant effect	Can reduce protamine use
Bivalirudin	Alternative procedural anticoagulant	May reduce heparin exposure
Direct oral anticoagulants	Chronic anticoagulation	Different clinical setting
Idarucizumab	Dabigatran reversal	Not a protamine substitute
Andexanet alfa	Selected factor Xa inhibitor reversal	Not a protamine substitute
Four-factor PCC	Selected anticoagulant reversal settings	Different mechanism and risk profile

The commercial threat is indirect. If procedural practice shifts away from heparin, protamine demand declines. Where heparin remains dominant, protamine retains a strong clinical position.

What generic entry risks exist for protamine sulfate?

Generic entry risk is moderate for approved finished injectable products but limited by technical and regulatory complexity.

A generic entrant must address:

• Active ingredient characterization.
• Sterility and endotoxin controls.
• Comparative strength and purity.
• Injectable stability.
• Container-closure integrity.
• Labeling and safety warnings.
• Manufacturing-site inspection.
• Hospital formulary and procurement requirements.

Price erosion can be substantial after multiple approved suppliers enter. However, the market may not attract many competitors because total addressable revenue is limited and the product requires specialized sterile capacity.

What is the geographic coverage of the protamine sulfate market?

The United States, Europe, Japan, China, and other developed healthcare markets account for the most regulated demand. Cardiac surgery volumes, insulin manufacturing, local registration requirements, and hospital procurement systems determine regional economics.

Geographic differences include:

• United States: FDA approval, hospital contracting, shortage monitoring, and reliance on approved sterile suppliers.
• European Union: national procurement combined with European Medicines Agency and national authority requirements.
• Japan: local regulatory and reimbursement requirements.
• China and India: growing pharmaceutical manufacturing capacity, with varying standards for biological source control and finished injectable registration.
• Emerging markets: demand exists, but access can be affected by import controls, cold-chain requirements, and limited hospital budgets.

Export controls and animal-origin documentation can create regional barriers even when the underlying product is technically available.

What is the outlook for protamine sulfate?

Protamine sulfate should remain a stable niche pharmaceutical ingredient and hospital injectable rather than a high-growth excipient platform.

The investment case depends on supply reliability, qualification status, and exposure to insulin or cardiac-care customers. Manufacturers with diversified biological sourcing, validated sterile capacity, and regulatory registrations in several jurisdictions are better positioned than distributors dependent on a single upstream source.

Revenue growth is likely to be constrained by the mature nature of heparin reversal and the gradual shift from NPH insulin toward analogs. Pricing power can remain resilient during shortages because hospitals cannot easily eliminate the product from emergency inventories.

Key Takeaways

• Protamine sulfate is both an active heparin-reversal drug and a formulation component in NPH and premixed insulin.
• The standalone market is not transparently reported by public companies.
• Financial growth is likely to come from pricing, supply security, and insulin demand rather than rapid unit expansion.
• The basic substance has limited current composition-of-matter patent protection.
• Process patents, regulatory approvals, manufacturing know-how, and qualified biological sourcing are the main competitive barriers.
• Biosimilar competition is not the primary risk; generic injectable entry and supplier qualification are more relevant.
• Demand is exposed to heparin use in cardiac and vascular procedures and to the market share of protamine-containing insulin.
• The product has a stable but specialized commercial profile with meaningful shortage and manufacturing risk.

FAQs About Protamine Sulfate Market and Intellectual Property

Is protamine sulfate an excipient or an active pharmaceutical ingredient?

It is both, depending on the product. In protamine sulfate injection, it is the active ingredient. In NPH and selected premixed insulin products, it is a formulation component that modifies insulin absorption.

Is protamine sulfate derived from fish?

Many commercial preparations have historically used fish-derived protamine, particularly material associated with salmon. The exact source depends on the manufacturer and product. Source documentation, impurity controls, and allergen-related risk management are important regulatory considerations.

Can a hospital replace protamine sulfate with another reversal agent?

There is no universally equivalent replacement for complete unfractionated-heparin neutralization. Alternative anticoagulation or reversal strategies may be used in selected clinical circumstances, but they are not automatically interchangeable with protamine.

Does protamine sulfate require cold-chain distribution?

Requirements depend on the finished product and label. Sterile injectable products may have controlled storage conditions, while raw materials and research-grade products can have different requirements. The applicable manufacturer label and quality agreement control the distribution conditions.

Why is protamine sulfate commercially important despite its small market size?

It is used in emergency and procedural medicine, where reliable availability has a value disproportionate to annual volume. The product also supports manufacturing of protamine-containing insulin formulations, creating a second demand channel.

References

1. U.S. Food and Drug Administration. (n.d.). Protamine sulfate injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

5. European Medicines Agency. (n.d.). Protamine sulfate and anticoagulation-reversal information. https://www.ema.europa.eu/